Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens.
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens.
复制标题
DOI：
10.1038/mtm.2016.30
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Xing Z
中科院分区：
文献类型：
--
作者：
Afkhami S;Yao Y;Xing Z
腺病毒代表了最广泛使用的疫苗设计病毒载体平台，在对抗细胞内传染病方面显示出巨大的潜力，而细胞内传染病要么缺乏有效的疫苗，要么传统的疫苗接种策略效果不佳。对腺病毒分子生物学的广泛了解使得新技术和试剂可用于有效生成腺病毒载体疫苗，用于临床前和临床评估。包括非人腺病毒载体在内的新型腺病毒载体已成为疫苗设计的进一步改进的载体。在这篇综述中，我们讨论了最新的腺病毒技术及其在疫苗开发中的应用。我们特别关注腺病毒载体疫苗在针对结核分枝杆菌、流感病毒和人类免疫缺陷病毒等粘膜病原体的粘膜免疫策略中的应用。
Adenoviruses represent the most widely used viral-vectored platform for vaccine design, showing a great potential in the fight against intracellular infectious diseases to which either there is a lack of effective vaccines or the traditional vaccination strategy is suboptimal. The extensive understanding of the molecular biology of adenoviruses has made the new technologies and reagents available to efficient generation of adenoviral-vectored vaccines for both preclinical and clinical evaluation. The novel adenoviral vectors including nonhuman adenoviral vectors have emerged to be the further improved vectors for vaccine design. In this review, we discuss the latest adenoviral technologies and their utilization in vaccine development. We particularly focus on the application of adenoviral-vectored vaccines in mucosal immunization strategies against mucosal pathogens including Mycobacterium tuberculosis, flu virus, and human immunodeficiency virus.